Septic shock, which is triggered by microbial products, is mainly characterised by inadequate tissue perfusion, which can lead to multiple organ dysfunction and death. An intense release of vasoconstrictors agents occurs in the early stages of shock, which can lead to ischemic injury. In this scenario, cGMP could play a key role in counterbalancing these agents and preventing tissue damage. Sildenafil, which is a phosphodiesterase-5 inhibitor, increases cGMP in smooth muscle cells and promotes vasodilation. Thus, the purpose of this study was to investigate the effect of treatment with sildenafil in the early stages of sepsis. Male rats were submitted to either cecal ligation and puncture (CLP) or a sham procedure. Eight h after the procedure, the CLP and sham groups were randomly assigned to receive sildenafil (10 mg/kg, gavage) or vehicle, and twelve or twenty-four h later the inflammatory, biochemical and haemodynamic parameters were evaluated. Sepsis significantly increased levels of plasma nitrate/nitrite (NOx), aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine, creatine kinase and lactate. Additionally, sepsis led to hypotension, hyporesponsiveness to vasoconstrictor, renal blood flow reduction and also increased lung and kidney myeloperoxidase. Sildenafil increased renal blood flow and reduced the plasma levels of creatinine, lactate and creatine kinase, as well as reducing lung myeloperoxidase. Thus, phosphodiesterase inhibition may be a useful therapeutic strategy if administered at the proper time.
Introduction
Sepsis remains a major worldwide healthcare problem, with consistently high mortality rates. In the presence of septic shock and associated multiple organ failure, mortality may approach 30-40% (Investigators et al., 2014; Zhou et al., 2014) . Furthermore, apart from the use of fluids, antibiotics, adrenergic pharmacology and organ support, which have been widely used since the 1950s, no targeted biological therapy has decreased sepsis mortality and none is currently considered as part of standard clinical practice (Seeley and Bernard, 2016) . However, mortality rates due to sepsis remain high and new treatments are required.
After the discovery of nitric oxide (NO) in 1987, it became clear that large amounts of NO are produced during sepsis, and that NO is involved in cardiovascular collapse (Fernandes and Assreuy, 2008) . However, all the nitric oxide synthase (NOS) inhibitors tested so far in clinical settings have caused undesired side effects, such as excessive vasoconstriction, which was the most likely reason for the interruption of a Phase III study with a NOS inhibitor in human sepsis (López et al., 2004) .
Cardiovascular hallmarks of septic shock are systemic vasodilatation and hypotension, accompanied by large increase in sympathetic nerve activity and the release of vasoconstrictor hormones (Lukewich and Lomax, 2014; May et al., 2012 ). An excess of vasoconstrictors can get out of control and cause adverse effects (Dunser and Hasibeder, 2009) . In this scenario, the production of NO by constitutive enzymes is essential to preserve a proper blood flow, thereby avoiding excessive tissue ischemia during sepsis.
Thus, if in late sepsis the up-regulation of NOS type II (NOS-2), and consequently high levels of NO and cGMP, mediates cardiovascular collapse (Nardi et al., 2014) , in early sepsis, when NO levels are not so high and there is a storm of vasoconstrictors, the vasodilation mediated by NO-sGC-cGMP could be critical to preserve a proper blood perfusion and avoid organ failure. This is especially important in the kidneys, where the release of norepinephrine can induce intense vasoconstriction in the afferent glomerular arterioles, which can result in filtration pressure decreasing, followed by a reduction in the glomerular filtration rate (Schrier, 2004) . This can lead to acute renal failure, which occurs in approximately 51% of patients with septic shock and contributes to poor outcomes (Rangel-Frausto et al., 1995) . Interestingly, we have previously shown that in early sepsis there is an impairment in guanylate cyclase activity (Fernandes et al., 2006) and the guanylate cyclase inhibitors lead to a reduction in cGMP levels and an increase in the mortality rate (Fernandes et al., 2009 ). Since cGMP is the main messenger for NO-mediated arterial vasodilatation, the reduced levels of this cyclic nucleotide may also contribute to renal vasoconstriction during sepsis (Schrier, 2004) .
Therefore, we hypothesise that cGMP could be essential to maintaining proper blood perfusion in early sepsis, mainly in the kidneys. Consequently, we evaluated the effect of sildenafil, which is a clinically approved phosphodiesterase-5 that inhibits the breakdown of cGMP, as a strategy to increase the bioavailability of cGMP in early sepsis.
Materials and methods

Animals
Male Wistar rats (200-250 g; 10 weeks old) were housed in a temperature and light-controlled room with free access to water and food. All the procedures were in accordance with the European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes, and the Guide of the Brazilian National Council of Animal Experimentation. The procedures were approved by the University's Institutional Ethics Committee (Protocol number 019/2013).
Cecal ligation and puncture (CLP)
CLP surgery was performed as previously described (Wichterman et al., 1980) with minor modifications. The rats were anesthetised with ketamine and xylazine (90 and 15 mg/kg, respectively). The cecum lumen was reduced by a non-obstructing ligation right above the ileocecal valve. The cecum was punctured twice with an 18-gauge needle and a small amount of cecal content was squeezed through the punctures. This was placed back in the cavity and the abdominal walls were sutured. The sham-operated rats underwent a similar surgical procedure with cecal exposure but it was neither ligated nor punctured. All the animals received 5 ml/100 g of sterile phosphate-buffered saline (PBS, in mM 137 NaCl, 2.7 KCl, 1.5 KH 2 PO 4 , and 8.1 NaHPO 4 ; pH 7.4) subcutaneously immediately after the procedure. PBS was administered for fluid resuscitation in order to reproduce clinical haemodynamic support and to induce a hyperdynamic phase circulatory state (Hubbard et al., 2005; Wichterman et al., 1980) . Bacteremia in the CLP rat model was confirmed through the analysis of whole blood obtained by cardiac puncture 12 h after the procedure (Table S1 ).
The rats were allowed to recover from anaesthesia in a pre-warmed fresh cage placed over a heating pad. The animals were monitored until full recovery, which took about 3 h. After recovery from anaesthesia, the animals were kept in a temperature and light-controlled room with free access to water and food until the time of analysis (see Section 2.10).
Cyclic GMP assay
For the assessment of the plasma cGMP levels, the blood was collected into EDTA tubes (7.5 mM) via a catheter inserted into the right carotid. Isobutyl-methylxanthine was immediately added (0.1 mM) to prevent cGMP breakdown and the blood was centrifuged (1800 G, 10 min, 4°C). Ice-cold ethanol was added to the samples and after five min the precipitation was removed by centrifugation (1800 G, 10 min, 4°C). The supernatant was dried under a stream of nitrogen and then the cGMP content was measured by ELISA (Cayman Chemical, Ann Arbor, USA) according to the manufacturer's instructions. The results were expressed as nM of cGMP.
Measurement of renal blood flow
The animals were anesthetised intramuscularly with ketamine and xylazine (90 and 15 mg/kg, respectively, supplemented at 50-min intervals) and then a transverse abdominal incision was performed to assess the posterior left subhepatic space, allowing the visualisation of the left kidney. A laser probe (model VP3), connected to a laser Doppler blood flow monitor (moorVMSLDF2, Moor Instruments, England) was carefully placed directly on the kidney, allowing the measurement of the renal blood flow (in arbitrary units). The probe was kept in this position and the surgical incision was covered with gauze sponges soaked in sterile phosphate-buffered saline to protect the kidney from drying. During the experiments, the animals were maintained on a warming pad and were allowed to breathe spontaneously. An interval of 20 min was allowed before the measurement of the basal values.
Mean arterial pressure (MAP) measurement
The animals were anesthetised as above, and heparinised PE-20 and PE-50 polyethylene catheters were inserted into the left femoral vein for the drug injections, and into the right carotid artery for MAP recording. To prevent clotting, a bolus dose of heparin (300 IU) was injected immediately after vein cannulation. The animals were allowed to breathe spontaneously via a tracheal cannula. The body temperature was monitored by a rectal thermometer and maintained at 36 ± 1°C by means of a heating table. The blood pressure and heart rate data were recorded with a catheter pressure transducer coupled to a Powerlab 4/ 30 (AD Instruments Pty Ltd., Castle Hill, Australia) running proprietary LabChart 8 ® software.
After stabilisation, the animals received intravenous injections containing either phenylephrine (3, 10 and 30 nmol/kg) or angiotensin II (3, 10 and 30 pmol/kg). The doses were injected in a total volume of 250 µl (including washing of the catheter). An interval of eight min was allowed for MAP stabilisation between each administration. The change in MAP (in mmHg) was calculated and compared between the groups. At the end of the experiment the animals were killed by a pentobarbital overdose.
Organ Bath
The animals were euthanised using an overdose of sodium pentobarbital (100 mg/kg, i.p.). The thoracic aorta was cleaned of surrounding fat and mounted in organ baths under a basal tension of 1 g. After 60 min of equilibration, the rings were exposed to 60 mM potassium chloride (KCl) twice. The last contraction was taken as the reference value for tension development. Following this, the rings were precontracted with phenylephrine (10 −6 M), and the relaxant response to acetylcholine (10 −5 M) was measured to determine the endothelial integrity. The ability of acetylcholine to induce at least 80% relaxation in phenylephrine-contracted preparations was used to confirm the integrity of the endothelium. Only endothelium-intact aortic rings were used in this study. Thus, the contraction response curves for phenylephrine (10 −9 to 3×10 −5 M) or KCl (10-90 mM) were constructed. The tension was recorded via isometric force transducers (Panlab, model TRI 201) coupled to a Powerlab 4/30 (AD Instruments Pty Ltd., Castle Hill, Australia) running proprietary LabChart 8 ® software.
2.7. Leukocyte and platelet counts; urea, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate and creatine kinase assays
The total leukocyte and platelet counts were determined by Cell Dyn 1400 (Abbott Diagnostics, Abbott Park, Illinois, USA). The levels of urea nitrogen, creatinine, AST, ALT, lactate and creatine kinase were measured using commercially available clinical assay kits (Gold Analisa Diagnostica, Minas Gerais, MG, Brazil).
NOx assay
Briefly, plasma samples were deproteinised by the addition of zinc sulphate (2%) and subjected to the conversion of nitrate to nitrite using Escherichia coli nitrate reductase for 3 h at 37°C, as previously described (Sordi et al., 2011) . The values were expressed as µM NOx (nitrate + nitrite).
Myeloperoxidase assay
After the blood pressure experiments, the lungs and kidneys were harvested. Briefly, the samples were homogenised (1:20 w-v) in icecold 20 mM sodium phosphate buffer (pH 7.4). After centrifuging (13,000 G, 10 min, 4°C), the supernatants were removed and the pellets were again homogenised in hexadecyltrimethylammonium bromide buffer (0.5% HTAB in 80 mM sodium phosphate buffer, pH 5.4). The supernatants were assayed for myeloperoxidase activity by measuring the H 2 O 2 -dependent oxidation of 3,3′,5,5′-tetramethylbenzidine (TMB). In its oxidised form, TMB has a blue colour, which was measured spectrophotometrically at 650 nm. The reaction mixture for analysis consisted of 30 µl of tissue sample, 180 µl of H 2 O 2 (final concentration 0.3 mM) diluted in 0.08 M phosphate buffer, pH 5.4, and 20 µl of TMB (final concentration 0.16 mM) dissolved in dimethylsulfoxide (DMSO). The reaction was performed in a 96-well microtiter plate. The mixture was incubated for 10 min at 37°C and the optical density (650 nm) was measured every two min. Five minutes incubation time was used for the lungs and 10 min for the kidneys. The myeloperoxidase activity was expressed as optical density at 650 nm per mg of protein.
Experimental protocol
Thirty-two animals were randomly distributed into two groups of 16 animals each and subjected to either CLP or a sham procedure. Eight h after the procedure, the CLP and sham groups were randomly assigned to receive sildenafil (10 mg/kg, gavage) or vehicle (1 ml/kg distilled water, gavage). Four h later (hence, 12 h after CLP or the sham procedure) the animals were prepared for the measurement of MAP and renal blood flow. At the end of the experiment, blood was collected in order to measure the levels of cGMP, creatinine, urea and NOx ( Fig. 1) and for blood bacteria analysis (Supplementary material).
In the second set of experiments, 32 animals were randomly distributed into two groups of 16 animals each and subjected to either CLP or a sham procedure. Eight h after the procedure, the CLP and sham groups were randomly assigned to receive sildenafil (10 mg/kg, gavage) or vehicle (1 ml/kg distilled water, gavage). Sixteen h later (hence 24 h after CLP or the sham procedure) the animals were prepared to record the MAP. At the end of the experiment, samples of blood and tissues for assays were obtained (Fig. 1) .
The dose of sildenafil was chosen based on pharmacokinetic (Shin et al., 2006) and toxicological studies (Abbott et al., 2004) in rats. Additionally, previous studies, after using several doses, revealed that 10 mg/kg was effective in rats (Yildirim et al., 2010) . The time of sildenafil treatment was chosen based on our previous studies about guanylate cyclase in sepsis (Fernandes et al., 2009 ) and also in the evaluation of effect of sildenafil on sodium nitroprusside response (Fig. S6) .
Statistical analysis
Data are expressed as the mean ± S.E.M. of eight rats. The statistical significance was analysed by two-way ANOVA, followed by Bonferroni's post hoc test. A P value less than 0.05 was considered to be significant. All the data presented normality and homogeneity of variances. These conditions had been proved by the Shapiro-Wilk and Bartlett test, respectively. Agonist concentration-response curves were fitted using a nonlinear regression. Agonist potencies and maximum responses were expressed as the negative logarithm of the molar concentration of agonist producing 50% of the maximum response (pEC50) and the maximum effect elicited by agonist (Max), respectively.
Compounds
Acetylcholine, phenylephrine, sodium nitroprusside, angiotensin II, isobutyl-methylxanthine and sildenafil citrate were purchased from Sigma Chemical, Co (St Louis, MO). Heparin was kindly donated by Cristália Laboratories (São Paulo, SP, Brazil).
Results
Effect of early treatment with sildenafil on cGMP plasma levels and renal blood flow
The CLP procedure alone did not change the cGMP plasma levels ( Fig. 2A) . However, treatment with sildenafil increased the level of cGMP serum by 100% in both the sham-treated and CLP-treated animals ( Fig. 2A , P < 0.001).
The renal blood flow was already reduced 12 h after the CLP procedure ( Fig. 2B , P < 0.001). There were also increases in the plasma levels of creatinine ( Fig. S1A , P < 0.001), urea ( Fig. S1B , P < 0.001) and NOx ( Fig. S1C , P < 0.001). Interestingly, in the CLP-treated animals, the increase in cGMP was associated with an improvement in renal blood flow (Fig. 2B , P < 0.05) and a reduction in plasma creatinine levels ( Fig. S1A , P < 0.01). Twelve h after CLP there was a slight reduction in blood pressure in the septic animals compared to the sham animals (approximately 7 mmHg; P > 0.05). The treatment with sildenafil did not change the blood pressure of the sham-treated animals (Fig. S2 ), but caused a reduction in the blood pressure of the CLPtreated animals ( Fig. S2 , P < 0.05).
Effect of sildenafil on CLP-induced cardiovascular changes
The CLP animals presented hypotension (Fig. 3A , P < 0.001), tachycardia ( Fig. 3B , P < 0.001) and an impairment in phenylephrine ( Fig. 3C , P < 0.001) and angiotensin II-response ( Fig. S3A , P < 0.001), therefore reproducing symptoms of human sepsis. Sildenafil failed to improve any of these cardiovascular parameters (Fig. 3 and Fig. S3A ).
We also investigated the vascular reactivity in isolated aortic rings. The aortic rings from rats subjected to CLP showed marked reductions in the concentration-response curve for phenylephrine ( Fig. 3D , P < 0.001) and KCl ( Fig. S3B , P < 0.01). The CLP procedure reduced the potency (pEC50, P < 0.05) and efficacy (Max, P < 0.01) of phenylephrine and the KCl contraction response (Table S2) . Interestingly, sildenafil induced a leftward shift in the concentration-response curve to phenylephrine in the sham-treated animals (Fig. 3D , Table S2 ) with no change in the maximal contractile effect (Max , Table S2 ). Nevertheless, the sildenafil treatment only induced a slight leftward Fig. 1 . Timeline of the protocol designed to study the role of cGMP in early sepsis. Eight h after the CLP or sham procedure the rats were assigned to receive either sildenafil (10 mg/kg, gavage) or water (1 ml/kg, gavage). Twelve or 24 h after the CLP or sham procedure the analyses were performed.
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European Journal of Pharmacology 807 (2017) 174-181 shift in the phenylephrine curve of the CLP groups, as shown by the increase in pEC50 (Table S2 , P < 0.05), with no change in the concentration response curve (Fig. 3D ) and maximal contractile effect (Table S2 ). The sildenafil treatment did not change the KCl contraction in the CLP-treated animals ( Fig. S3B and Table S2 ). The comparison of the pEC50 mean differences between the two independent variables (sepsis and sildenafil treatment) by two-way ANOVA revealed no interaction between these factors (P=0.844), showing that the ability of sildenafil to increase the potency of phenylephrine was independent of the septic state.
Effect of sildenafil on CLP-induced organ dysfunction and systemic inflammation parameters
The septic control animals exhibited an increase in levels of plasma creatinine, urea, AST, ALT, lactate, creatine kinase and NOx when compared with the sham animals (Fig. 4) . Sildenafil treatment reduced the levels of CLP-induced creatinine ( Fig. 4A , P < 0.05), lactate ( Fig. 4E , P < 0.05) and creatine kinase (Fig. 4F , P < 0.001). The levels of urea, AST, ALT and NOx were not changed by the sildenafil treatment (Fig. 4) .
There was also an increase in myeloperoxidase activity levels in the lungs and kidneys of the CLP animals ( Fig. 5A and B, respectively) . Treatment with sildenafil reduced the myeloperoxidase activity in the CLP-treated lungs (Fig. 5A , P < 0.05) but failed to do the same in the kidneys (Fig. 5B) .
Effect of sildenafil on CLP-induced haematological changes
The septic group developed leukopenia (Fig. S4A) and lymphopenia when compared with the sham group (Fig. S4E-F) . There was an increase in the relative number of neutrophils (Fig. S4C) but there was no change in the absolute number of neutrophils (Fig. S4D) . Sepsis also caused a reduction in the platelet number (Fig. S4B) . None of these haematological parameters were changed by the effect of sildenafil (Fig.  S4) .
Discussion
The present study demonstrated that the inhibition of phosphodiesterase-5 by sildenafil in early sepsis increased plasmatic cGMP, which was associated with an improvement in renal blood flow and a reduction in plasma creatinine levels during sepsis. Additionally, treatment with sildenafil reduced plasma levels of lactate and creatine kinase. These data suggest that an increase in cGMP levels in early sepsis improves tissue blood flow and attenuates tissue damage and organ dysfunction.
The high levels of NO produced by NOS-2, and consequent excess of cGMP during sepsis, are generally associated with hypotension, low tissue perfusion and a poor outcome (Assreuy, 2006) . In accordance with this idea, it has been shown that in late experimental sepsis there were increases in levels of guanylate cyclase and cGMP (Fernandes et al., 2009; Nardi et al., 2014) . The inhibition of guanylate cyclase in late sepsis has been shown to reduce cGMP levels, to reduce organ damage, and to improve survival in an experimental model of sepsis (Fernandes et al., 2009 ). On the other hand, early sepsis has been associated with impairing soluble guanylate cyclase (Fernandes et al., 2006) and the inhibition of this enzyme in this sepsis stage has been associated with increasing levels of mortality (Fernandes et al., 2009 ). The present study found that in early sepsis (12 h), despite increased levels of nitric oxide, there was no increase in cGMP levels and no reduction in blood pressure. The aforementioned studies suggest that cGMP could play a key role in maintaining a proper blood flow and avoiding tissue ischemia in early sepsis.
The effects of cGMP responses are determined by the balance between its synthesis by guanylate cyclase, and its degradation by phosphodiesterases. Among the highly diverse superfamily of phosphodiesterases (Bobin et al., 2016) , phosphodiesterase-5 is one of the only three enzymes that selectively hydrolyse cGMP relative to cAMP (Stegbauer et al., 2013) . Furthermore, phosphodiesterase-5 is highly abundant in vascular smooth muscle (Rybalkin et al., 2003) , and by limiting the breakdown of cGMP, phosphodiesterase-5 inhibition potentiates the vasorelaxant effect of NO/cGMP (Martin et al., 1986) . Thus, to study the role of cGMP in early sepsis we used sildenafil, which is a high selective phosphodiesterase-5 inhibitor, as a pharmacological tool to increase the cGMP levels.
We performed a single dose treatment at early sepsis (8 h after CLP) to increase cGMP levels around the time that guanylate cyclase cGMP is impaired (Fernandes et al., 2009 (Fernandes et al., , 2006 and we evaluated cardiovascular parameters, markers of inflammation and organ damage 24 h after CLP, when the septic shock is fully established (Fernandes et al., 2009) . After oral administration in rats, sildenafil is rapidly and nearly completely absorbed from the gastrointestinal tract, reaching a maximum concentration (Tmax) in 11.1 min for 10 mg/kg. The terminal half-life is about 41 min (Shin et al., 2006) . Accordingly, the maximum effect of a single dose of sildenafil was around 9-10 h after CLP or the sham procedure, which is in accordance with the increased levels of cGMP 12 h after the procedure. Therefore, we succeeded in increasing the cGMP levels around the time the guanylate cyclase activity was impaired (Fernandes and Assreuy, 2008) , and also when there was already an established low renal blood flow.
Despite low blood pressure and hyporesponsiveness to vasocon- Fig. 2 . Effect of CLP and sildenafil on serum cGMP levels and renal blood flow. The rats received sildenafil (10 mg/kg, gavage) or vehicle (water, 1 ml/kg, gavage) 8 h after CLP or sham procedure. Twelve h after surgery the animals were prepared for the measurement of renal blood flow (B) and blood was obtained to measure cGMP (A). Each bar represents the mean of eight animals, and the vertical lines represent the S.E.M. Statistical analyses were performed using two-way analysis of variance followed by Bonferroni's post-hoc test. *P < 0.05; **P < 0.01; ***P < 0.001. strictors in sepsis, there is a vasoconstriction in the kidneys (Guarido et al., 2014) , which, together with a low cardiac output, is responsible for acute kidney injury (Shum et al., 2016) . In this scenario, the activation of the sympathetic nervous system, associated with the adrenergic support treatment in sepsis, can induce a profound vasoconstriction in the afferent glomerular arterioles, decreasing filtration pressure and consequently decreasing the glomerular filtration rate. This is in accordance with the CLP-induced reduction in the renal blood flow. Interestingly, sildenafil increased the renal blood flow and reduced plasmatic creatinine levels, indicating an improvement in glomerular filtration. Therefore, cGMP-induced relaxation could be essential to preserve kidney function in early sepsis. Sildenafil treatment also reduced levels of lactate and creatine kinase, showing an improvement in tissue perfusion and damage. Intriguingly, sildenafil failed to increase renal blood flow in the sham-treated group. This result agrees with a recent study which showed that phosphodiesterase-5 inhibition did not change renal blood flow in a control group, but it increased in mice continuously infused with angiotensin II (Thieme et al., 2017) , which reduces renal blood flow (Fig. S5) . Thus, the effect of sildenafil appears to be important in reducing renal blood flow conditions such as sepsis. The increase in cGMP sensitivity in sepsis (McKenna, 1988) can also explain the selective effect of sildenafil in this group of animals.
In the present study, sildenafil treatment failed to prevent hypotension or to improve the phenylephrine or angiotensin II-induced increase in blood pressure of the septic animals. Interestingly, sildenafil increased the potency of phenylephrine in the isolated aorta experiments for both the sham and CLP-treated groups. However, the effect on the CLP-treated animals was very modest, with probably no biological relevance. On the other hand, in the case of the sham-treated animals, sildenafil expressively increased the potency of phenylephrine. A previous study showed that sildenafil had the opposite effect, relaxing phenylephrine pre-contract aorta (Sharabi et al., 2005) . However, in the aforementioned study, sildenafil was incubated with the aorta, which was different from our protocol, where the animals received sildenafil by gavage 16 h before the aorta was harvested for the organ bath experiment. Unfortunately, we do not have a good explanation for this effect, which may even be independent of the NO/cGMP pathway (Elrod et al., 2007) . Further research is needed to delineate the precise mechanisms by which sildenafil affects vasoconstriction response in the aorta.
Sildenafil was also able to reduce neutrophil sequestration within the lungs of the CLP-treated animals, as demonstrated by the reduction in myeloperoxidase activity. Myeloperoxidase is considered a marker of neutrophil recruitment, which has been suggested plays an important role in sepsis-induced lung injury (Perl et al., 2011) . The lungs are the preferred site for the accumulation of activated blood neutrophils, due to the long and narrow microvascular bed (Song et al., 2012) . This effect is especially important in sepsis, which induces pulmonary vasoconstriction (Weitzberg et al., 1993) . Phosphodiesterase-5 is abundant in lung tissues, and it modifies the pulmonary vasodilatory response to exogenous NO (Sanchez et al., 1998) . Therefore, sildenafil could decrease pulmonary vascular resistance and capillary pressure, preserving microvascular perfusion and facilitating the transit of activated leukocytes. Thus, by reducing neutrophil sequestration into the lungs, sildenafil could play a role in preventing lung injury in sepsis. Fig. 3 . Effect of CLP and sildenafil on blood pressure and hyporesponsiveness to vasoconstrictors. The rats received sildenafil (10 mg/kg, gavage) or vehicle (water, 1 ml/ kg, gavage) 8 h after CLP or sham procedure. Twenty-four h after surgery the animals were prepared to record their mean arterial pressure (A) and heart rate (B). Increasing doses of phenylephrine (C) were injected (i.v.) and changes in MAP were recorded. Additionally, the aortic rings were mounted and cumulative concentration curves of phenylephrine were determined (D). Each bar or point represents the mean of eight animals and the vertical lines represent the S.E.M. Statistical analyses were performed using two-way analysis of variance followed by Bonferroni's post-hoc test. *P < 0.05, ***P < 0.001. Fig. 4 . Effect of CLP and sildenafil on plasma markers of organ dysfunction and inflammation. The rats received sildenafil (10 mg/kg, gavage) or vehicle (water, 1 ml/kg, gavage) 8 h after CLP or sham procedure. Twenty-four h after surgery, blood was obtained to assess creatinine (A), urea (B), AST (C), ALT (D), lactate (E), creatine kinase (F) and nitrate +nitrite (NOx, G). Each bar represents the mean of eight animals and the vertical lines represent the S.E.M. Statistical analyses were performed using two-way analysis of variance followed by Bonferroni's post-hoc test. *P < 0.05, **P < 0.01, ***P < 0.001.
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European Journal of Pharmacology 807 (2017) 174-181 Despite improving renal blood flow and reducing plasma creatinine levels in sepsis, sildenafil failed to reduce myeloperoxidase levels in the kidneys. This supports the idea that the reduction of plasma creatinine levels was a consequence of the increased renal blood flow and the improvement in glomerular filtration, instead of the reduction in kidney inflammation. It is worth mentioning that the levels of myeloperoxidase in the kidneys were about 100 times lower that in the lungs. Thus, perhaps neutrophil migration does not play a key role in damaging the kidneys during sepsis. This agrees with previous studies which showed that despite systemic vascular changes, most of the neutrophils are preferentially sequestered into the lungs (Andonegui et al., 2003) . Using the same CLP model, a previous study demonstrated that sildenafil reduced myeloperoxidase levels in the lungs and kidneys (Cadirci et al., 2011) . However, the aforementioned authors treated the animals immediately after the surgical procedure, thus, before the animals had developed proper sepsis or septic shock.
Sepsis is a very dynamic process, with the NO/cGMP pathway playing different roles over time. A previous study demonstrated that endothelium-dependent relaxation increased at 2 h, returned to control levels at 3.5 h, but decreased afterwards (Wang et al., 1994) . Additionally, in early endotoxemia, a small amount of cGMP is produced in the heart, which seems to be beneficial to maintaining myocardial contractile capacity. However, large amounts of cGMP produced later seem to mediate heart depression (Cohen et al., 2006) . Altogether, these data agree with the present study that early sepsis is a proper moment to increase cGMP levels. However, increasing cGMP at a different time point could result in a different outcome.
As the population becomes increasingly old and ill, most septic patients are elderly people who present comorbidities (Girard et al., 2005) . However, in the present study, we induced sepsis in young adult and healthy rats, which clearly limits translational applicability. Also, the conclusions about cGMP cannot be extrapolated to NO, which reaches targets other than guanylate cyclase. Lastly, further studies are needed to assess the tissue phosphodiesterase expression during sepsis development.
In summary, we have demonstrated that early treatment with sildenafil, which is a phosphodiesterase-5 inhibitor, increases renal blood flow and improves renal function in sepsis. Additionally, sildenafil improves tissue oxygenation and reduces injury. Thus, increasing cGMP levels at the early stage of sepsis may provide proper tissue blood flow, thereby preventing ischemic damage. Therefore, phosphodiesterase-5 inhibition may be a useful therapeutic strategy if administered at the appropriate time. Fig. 5 . Effect of CLP and sildenafil on tissue myeloperoxidase. The rats received sildenafil (10 mg/kg, gavage) or vehicle (water, 1 ml/kg, gavage) 8 h after CLP or sham procedure. Twenty-four h after surgery, sample tissues from the lungs (A) and kidneys (b) were obtained to measure myeloperoxidase activity. Each bar represents the mean of eight animals and the vertical lines represent the S.E.M. Statistical analyses were performed using two-way analysis of variance followed by Bonferroni's post-hoc test. *P < 0.05.
